Jump Financial LLC Raises Position in REGENXBIO Inc. (NASDAQ:RGNX)

Jump Financial LLC grew its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 144.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 192,708 shares of the biotechnology company's stock after buying an additional 114,005 shares during the period. Jump Financial LLC owned 0.39% of REGENXBIO worth $1,490,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of RGNX. Walleye Capital LLC purchased a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $681,000. XTX Topco Ltd lifted its stake in shares of REGENXBIO by 720.5% in the fourth quarter. XTX Topco Ltd now owns 108,120 shares of the biotechnology company's stock valued at $836,000 after purchasing an additional 94,943 shares during the period. Barclays PLC boosted its holdings in REGENXBIO by 9.5% during the fourth quarter. Barclays PLC now owns 127,065 shares of the biotechnology company's stock worth $982,000 after buying an additional 11,041 shares in the last quarter. Raymond James Financial Inc. acquired a new position in REGENXBIO during the fourth quarter worth about $568,000. Finally, Renaissance Technologies LLC purchased a new position in REGENXBIO in the fourth quarter valued at about $2,097,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

REGENXBIO Trading Down 0.8 %

Shares of NASDAQ RGNX traded down $0.07 on Friday, reaching $9.13. 166,268 shares of the company traded hands, compared to its average volume of 813,432. The stock has a market capitalization of $457.42 million, a PE ratio of -1.81 and a beta of 1.26. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $17.52. The company has a 50 day moving average of $6.88 and a 200 day moving average of $8.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. As a group, research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGNX has been the topic of a number of research reports. The Goldman Sachs Group lowered their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada reissued an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Raymond James initiated coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target on the stock. Finally, Morgan Stanley lifted their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, REGENXBIO presently has a consensus rating of "Moderate Buy" and an average target price of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.